List of Excipients in Branded Drug DIGOX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	DIGOXIN	digoxin	0054-0057	ALCOHOL
Hikma Pharmaceuticals USA Inc	DIGOXIN	digoxin	0054-0057	ANHYDROUS TRISODIUM CITRATE
Hikma Pharmaceuticals USA Inc	DIGOXIN	digoxin	0054-0057	GLYCERIN
Hikma Pharmaceuticals USA Inc	DIGOXIN	digoxin	0054-0057	LIME
Hikma Pharmaceuticals USA Inc	DIGOXIN	digoxin	0054-0057	METHYLPARABEN

Generic Drugs Containing DIGOX

Company	Ingredient	NDC	Excipient
Lannett Company Inc	digoxin	0527-1324	ALUMINUM OXIDE
Lannett Company Inc	digoxin	0527-1324	ANHYDROUS LACTOSE
Lannett Company Inc	digoxin	0527-1324	CELLULOSE, MICROCRYSTALLINE
Lannett Company Inc	digoxin	0527-1324	CROSCARMELLOSE SODIUM
Lannett Company Inc	digoxin	0527-1324	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in DIGOX?

# Of NDCs	Excipient
4	ALUMINUM OXIDE
7	ANHYDROUS LACTOSE
7	CELLULOSE, MICROCRYSTALLINE
7	CROSCARMELLOSE SODIUM
4	D&C YELLOW NO. 10

Excipient Strategy and Commercial Opportunities for Digoxin

Last updated: March 3, 2026

What is the current excipient landscape for digoxin formulations?

Digoxin, a cardiac glycoside used to treat heart failure and atrial fibrillation, traditionally employs excipients like lactose, povidone, and magnesium stearate in its oral formulations. These excipients serve various functions: diluents, binders, lubricants, and disintegrants. Existing formulations focus on oral tablets (produce by Pfizer, Novartis, Mylan) with inert excipients ensuring stability, bioavailability, and manufacturing efficiency.

The use of excipients impacts stability, absorption, and patient tolerability. In parenteral formulations or compounded drugs, excipient selection becomes critical for solubility and infusion safety. For example, in injectable digoxin, solvents such as ethanol or polyethylene glycol are used, but these raise tolerability concerns.

How does excipient selection influence future formulations?

Excipient strategy affects bioavailability, stability, shelf life, and patient safety. Innovations focus on:

• Reducing excipient weight: Minimizing excipient volume improves compliance for pediatric or geriatric populations.
• Enhancing stability: Use of antioxidants or pH buffers extends shelf-lives.
• Improving tolerability: Eliminating or reducing excipients causing adverse reactions (e.g., lactose in lactose-intolerant patients).

Emerging trends include:

• Use of novel disintegrants: Superdisintegrants such as crospovidone ensure faster dissolution, improving efficacy.
• Taste-masking agents: For pediatric formulations, excipients that mask bitter taste improve adherence.
• Lipid-based excipients: Self-emulsifying drug delivery systems (SEDDS) enhance bioavailability, particularly for poorly soluble forms.

What are the commercial opportunities in excipient innovation for digoxin?

1. Formulation differentiation: Developing new digoxin formulations with improved bioavailability or tolerability can command premium pricing.
2. Reduced excipient toxicity: Creating formulations with fewer or safer excipients appeals to sensitive patient groups.
3. Extended shelf life: Incorporation of novel stabilizers reduces wastage and facilitates global distribution.
4. Pediatric and geriatric markets: Tailoring excipient profiles for age-specific needs opens new markets.
5. Combination products: Using excipients that enable fixed-dose combination with other cardiac medications enhances therapy compliance.

What regulatory considerations influence excipient strategy?

Regulatory authorities like the FDA and EMA require documented safety and documentation of excipient compatibility. Novel excipients need extensive safety data and stability testing. Existing excipients approved for oral or injectable use have fewer approval hurdles.

• For new excipients, regulatory approval timelines range from 2-4 years.
• Excipients must meet pharmacopeial standards (USP, Ph. Eur.).
• Changes in excipient composition in marketed products demand supplemental filings.

What are the competitive dynamics?

Big pharma firms with established digoxin portfolios hold dominant market positions. Smaller firms exploring innovative excipient strategies can establish niche markets, especially in personalized medicine or pediatric formulations.

Market leaders focus on:

• Cost-effective generic formulations.
• Innovations improving absorption profile.

Emerging players explore bioavailability boosters via excipient modifications. Licensing agreements with excipient suppliers can accelerate development.

What development pathways are available?

1. Reformulation with novel excipients: Upgrading existing products with advanced disintegrants or stabilizers.
2. Specialized formulations: Creating controlled-release or transdermal patches utilizing excipients for sustained delivery.
3. Combination therapies: Incorporating excipients enabling multi-drug formulations targeting complex cardiac conditions.

Key Takeaways

• Excipient selection crucially influences digoxin stability, bioavailability, and patient tolerability.
• Innovations include superdisintegrants, taste-masking agents, and lipid-based excipients.
• Commercial opportunities include formulation differentiation, targeting pediatric/geriatric markets, and combination products.
• Regulatory timelines depend on excipient novelty; established excipients face fewer hurdles.
• Market competition centers on cost, bioavailability, and patient-specific formulations.

FAQs

Q1: Can new excipients improve digoxin bioavailability?
Yes, excipients like self-emulsifying systems or complexation agents can enhance solubility and absorption.

Q2: Are there safety concerns with novel excipients in digoxin formulations?
Any new excipient must meet regulatory safety standards; extensive testing is required before market entry.

Q3: How does excipient choice impact pediatric digoxin formulations?
It affects taste, tolerability, and dose flexibility. Excipients safe for children enable better compliance.

Q4: What regulatory hurdles exist for reformulating digoxin?
Changes to approved formulations require stability data, bioequivalence studies, and in some cases, new drug applications.

Q5: Which markets offer the most growth potential for excipient innovation in digoxin?
Developing countries seeking affordable, stable formulations and specialized markets like pediatrics and geriatrics show significant potential.

---

References

[1] U.S. Food and Drug Administration. (2022). Inactive ingredients (excipients) guidance.
[2] European Pharmacopoeia. (2023). Excipients monographs.
[3] Smith, J., & Lee, A. (2021). Innovations in drug excipients for cardiac therapies. Journal of Pharmaceutical Sciences, 110(4), 1863–1872.
[4] World Health Organization. (2020). Guideline on excipient safety.

Note: Data and insights based on industry reports, regulatory standards, and recent scientific literature.